



Alvogen®
Teriparatide Injection
20 mcg per dose. Each single-patient-use pen will deliver 28 subcutaneous doses.

SAVINGS PROGRAM

No Activation Required.
Commercially insured patients only.
Limitations apply.
\$12,000 annual maximum benefit.

BIN# 600426
PCN# 54
GRP# ECALVOGEN
ID# ALVOGEN

Pay as little as \$0

Pharmacist and Beneficiary:
When you use this card, you are certifying that you have not submitted and will not submit a claim for reimbursement under any federal, state, or other governmental programs for this prescription.

Eligible patients can pay as little as \$0 and receive up to \$12,000 off the patient's co-pay or out of pocket expenses annually of Teriparatide Injection, Solution. Maximum monthly benefit applies. A valid Prescriber ID# is required on the prescription.

Patient Instructions: In order to redeem this offer you must have a valid prescription for Teriparatide Injection, Solution. Follow the dosage instructions given by the doctor. This offer may not be redeemed for cash. By using this offer, you are certifying that you meet the eligibility criteria and will comply with the terms and conditions described in the Restrictions section below. Patients with questions about Teriparatide Injection, Solution Savings offer should call 833.330.0806.

Pharmacist instructions for a patient with an Eligible Third Party: Submit the claim to the primary Third Party Payer first, then submit the balance due to **CHANGE HEALTHCARE** as a Secondary Payer (COB [coordination of benefits] with patient responsibility amount and a valid Other Coverage Code, (e.g., 8). The patient is responsible for the first \$0 and the card pays up to the next \$12,000. Reimbursement will be received from **CHANGE HEALTHCARE**. Valid Other Coverage Code required. For any questions regarding **Change Healthcare** online processing, please call the Help Desk at **800.433.4893**.

Pharmacist: When you apply this offer, you are certifying that you have not submitted a claim for reimbursement under any federal, state, or other governmental programs for this prescription. Participation in this program must comply with all applicable laws and regulations as a pharmacy provider. By participating in this program, you are certifying that you will comply with the terms and conditions described in the Restrictions section. **Restrictions:** This offer is valid in the United States. Offer not valid for prescriptions reimbursed under Medicaid, a Medicare drug benefit plan, Tricare or other federal or state health programs (such as medical assistance programs). Cash Discount Cards and other non-insurance plans are not valid as primary under this offer. If the patient is eligible for drug benefits under any such program, the patient cannot use this offer. By using this offer, the patient certifies that he or she will comply with any terms of his or her health insurance contract requiring notification to his or her payor of the existence and/or value of this offer. It is illegal to (or offer to) sell, purchase, or trade this offer. This offer is not transferable and is limited to one offer per person. Not valid if reproduced. Void where prohibited by law. Program managed by ConnectiveRx on behalf of Alvogen Pharmaceuticals. The parties reserve the right to rescind, revoke or amend this offer without notice at any time.

Indications

Teriparatide Injection is a prescription medicine used in both men and postmenopausal women with osteoporosis who are at high risk for having bone fractures—defined as those who have had a fracture related to osteoporosis, who are at high risk for fracture, or who cannot use other osteoporosis treatments. It is also used for treating osteoporosis associated with glucocorticoid medicines, such as prednisone, in patients who are at high risk for fracture.

Important Safety Information

WARNING: Potential Risk of Osteosarcoma

During drug testing, Teriparatide Injection caused some rats to develop a serious, but rare, bone cancer called osteosarcoma. It is not known if people who take Teriparatide Injection are at a higher risk of contracting osteosarcoma. Before taking, advise your healthcare provider if you have Paget's disease of bone, are a child or young adult whose bones are still growing, or have undergone radiation therapy.

Do not use Teriparatide Injection if you are allergic to any of its ingredients. Serious allergic reactions may occur.

Before taking Teriparatide Injection, inform your healthcare provider if you have a bone disease other than osteoporosis, have cancer in your bones, have trouble injecting yourself, are a child or young adult whose bones are still growing, have or have had kidney stones, have had radiation therapy, have been diagnosed with too much calcium in your blood, are pregnant or thinking about becoming pregnant, are breastfeeding or plan to breastfeed, or have any other medical conditions. Tell your healthcare provider about all the medicines you take, especially medicines that contain digoxin.

Teriparatide can cause serious side effects, including a decrease in blood pressure upon changing positions. Dizziness, accelerated heartbeat, or a feeling of faintness may occur, usually within four hours of taking Teriparatide Injection, and typically subside within a few hours. You should not use Teriparatide Injection for more than two years during your lifetime.

Other side effects include nausea, vomiting, constipation, low energy, joint aches, pain, leg cramps, or muscle weakness, which may be signs of too much calcium in your blood.

Injection site reactions can include pain, swelling and bruising.

If symptoms persist, stop taking Teriparatide Injection and call your healthcare provider.

Visit www.fda.gov/medwatch or call 1.800.FDA.1088 to report any additional negative side effects to the FDA.

For additional safety information, please see the Medication Guide and Prescribing Information, including the full User Manual which accompanies the delivery device.

